Kyungjin Peter Kim, CEO of ST Pharm, provides an insight into his expansion of the company’s operations from simply a CMO into a CDMO and new drug development. He also explains his decision to focus on manufacturing oligonucleotides, the potential in that market, and the challenges to the next objectives.
When I first visited ST Pharm, I appreciated its potential to become a global CDMO based on its experience and capabilities. I also devised many possibilities of starting up new drug development in Korea
